Ketoconazole, cytochrome P450 inhibitor

Alternative names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 20 lyase, 2700049B16Rik, 3110031N04Rik, A830040C14Rik, ACEE, ACES_HUMAN, AChR, AIS, ANDR_HUMAN, APOPAIN, AR, AR8, ARACHE, Acetylcholinesterase, Albendazole monooxygenase, Albendazole sulfoxidase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Apoptosis related acetylcholinesterase, Apoptotic protease Mch-3, Atherosclerosis, susceptibility to, included, BK channel, BK channel beta subunit, BK channel subunit beta-1, BK channel subunit beta-2, BK channel subunit beta-4, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, BKbeta2, BKbeta4, CAPC, CASP3_HUMAN, CASP7_HUMAN, CC3, CHRM1, CMH-1, CP17A_HUMAN, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC12, CPC8, CPC9, CPCJ, CPP-32, CPP32B, CPT7, CYP17, CYP17A1, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIC9, CYPIIIA3, CYPIIIA4, CYPXVII, Calcium activated potassium channel beta 4 subunit, Calcium activated potassium channel subfamily M subunit beta 1, Calcium activated potassium channel subfamily M subunit beta 2, Calcium activated potassium channel subfamily M subunit beta 4, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Calcium-activated potassium channel subunit beta-2, Calcium-activated potassium channel subunit beta-4, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase 7, Caspase 7 apoptosis related cysteine peptidase, Caspase-3, Caspase-3 subunit p12, Caspase-7 subunit p11, Charybdotoxin receptor subunit beta-1, Charybdotoxin receptor subunit beta-2, Charybdotoxin receptor subunit beta-4, Cholinergic receptor muscarinic 1, Cysteine protease CPP32, Cytochrome P-450MP, Cytochrome P450 17A1, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 17, Cytochrome P450 family 17 subfamily A polypeptide 1, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-C17, Cytochrome P450-PCN1, Cytochrome p450 XVIIA1, Cytochrome p450 subfamily XVII (steroid 17 alpha hydroxylase) adrenal hyperplasia, Cytokeratin-associated protein in cancer, DHTR, DKFZp686N23123, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Drosophila slowpoke like, EC 3.4.22.56, ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, Glucocorticoid inducible P450, HDL cholesterol, augmented response of, to hormone replacement, included, HLP, HM1, HUMARA, HYSP1, Hbeta1, Hbeta2, Hbeta3, Hbeta4, ICE-LAP3, ICE-like apoptotic protease 3, ICE3, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, K(VCA)beta-2, K(VCA)beta-4, KCMA1_HUMAN, KCMB1_HUMAN, KCMB2_HUMAN, KCMB4_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCNMB 2, KCa1.1, KD, Kennedy disease (KD), LICE, LICE2, LRC26_HUMAN, Large conductance Ca2+ activated K+ channel beta 1 subunit, Large conductance Ca2+ activated K+ channel beta2 subunit, Large conductance calcium activated potassium channel beta 2 subunit, Large conductance calcium dependent potassium ion channel beta 4 subunit, Leucine-rich repeat-containing protein 26, Lrrc26, MCH3, MGC126680, MGC149605, MGC22431, MGC57945, MGC88320, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi K channel subunit beta-2, Maxi K channel subunit beta-4, Maxi Potassium channel alpha, MaxiK, MaxiK channel beta 2 subunit, Microsomal monooxygenase, Muscarinic acetylcholine receptor M1, Myocardial infarction, susceptibility to, included, N-ACHE, NF 25, NR3A1, NR3A2, NR3B1, NR3C3, NR3C4, Nifedipine oxidase, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 3, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000020135, OTTHUMP00000020382, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, P450 C17, P450 III steroid inducible, P450 MP, P450 PB 1, P450 PCN1, P450, family III, P450C2C, P450C3, P450IIC19, P450IIC9, PARP cleavage protease, PGR, PR, PRA, PRB, PRGR_HUMAN, Potassium large conductance calcium activated channel subfamily M beta member 1, Potassium large conductance calcium activated channel subfamily M beta member 2, Potassium large conductance calcium activated channel subfamily M beta member 4, Procaspase3, Progesterone receptor, Progestin receptor form A, Progestin receptor form B, Protein Yama, Quinine 3-monooxygenase, RNESTROR, S-mephenytoin 4-hydroxylase, S17AH, SAKCA, SBMA, SCA-1, SLO, SMAX1, SREBP cleavage activity 1, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo-beta-2, Slo-beta-4, Slo1, Slowpoke homolog, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid 17 alpha hydroxylase/17,20 lyase, Steroid 17-alpha-hydroxylase/17, Steroid 17-alpha-monooxygenase, Steroid hormone receptor ERR1, TFM, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Xenobiotic monooxygenase, YT, YT blood group, Yama, Yama protein, androgen receptor splice variant 4b, bA350O14.10, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytokeratin-associated protein, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, hSlo, hslo beta, mldy, subfamily M subunit alpha-1, subfamily M subunit beta-1, subfamily M subunit beta-2, subfamily M subunit beta-4